Zensera

Zentera Therapeutics is a clinical-stage biopharmaceutical company headquartered in Shanghai, focused on developing and commercializing oncology therapies for the Chinese market. Founded as a joint venture by Zentalis Pharmaceuticals and a syndicate of investors, the company leverages Zentalis's discovery engine to advance a pipeline of small molecule candidates. Its lead programs include ZN-c3, a selective WEE1 inhibitor, and ZN-c5, an oral selective estrogen receptor degrader (SERD). Zentera aims to address significant unmet medical needs in cancer treatment through strategic partnerships and localized clinical development in China.